Reply to: Stereotactic radiotherapy needs more evidence before it can be used routinely to treat metastases: A comment on the paper by Nicosia et al

Affiliations

¹ Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Italy. Electronic address: luca.nicosia@sacrocuore.it.
² Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
³ Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Italy.
⁴ IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University Pieve Emanuele, Milan, Italy.
⁵ Department of Radiation Oncology, "Sapienza" University, Sant'Andrea Hospital, Rome, Italy.
⁶ Ecomedica Radioterapia, Empoli, Italy.
⁷ Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Italy; University of Brescia, Brescia, Italy.

Comment

Luca Nicosia et al. Radiother Oncol. 2022 Apr.

. 2022 Apr:169:161-162.

doi: 10.1016/j.radonc.2022.02.004. Epub 2022 Feb 11.

¹ Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Italy. Electronic address: luca.nicosia@sacrocuore.it.
² Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
³ Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Italy.
⁴ IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University Pieve Emanuele, Milan, Italy.
⁵ Department of Radiation Oncology, "Sapienza" University, Sant'Andrea Hospital, Rome, Italy.
⁶ Ecomedica Radioterapia, Empoli, Italy.
⁷ Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Italy; University of Brescia, Brescia, Italy.

No abstract available

Keywords: Colorectal cancer; Oligometastatic disease; Predictive factors; SABR; SBRT; Stereotactic ablative radiotherapy.

Comment on

A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study.
Nicosia L, Franceschini D, Perrone-Congedi F, Casamassima F, Gerardi MA, Rigo M, Mazzola R, Perna M, Scotti V, Fodor A, Iurato A, Pasqualetti F, Gadducci G, Chiesa S, Niespolo RM, Bruni A, Alicino G, Frassinelli L, Borghetti P, Di Marzo A, Ravasio A, De Bari B, Sepulcri M, Aiello D, Mortellaro G, Sangalli C, Franceschini M, Montesi G, Aquilanti FM, Lunardi G, Valdagni R, Fazio I, Scarzello G, Corti L, Vavassori V, Maranzano E, Magrini SM, Arcangeli S, Gambacorta MA, Valentini V, Paiar F, Ramella S, Di Muzio NG, Livi L, Jereczek-Fossa BA, Osti MF, Scorsetti M, Alongi F. Nicosia L, et al. Radiother Oncol. 2022 Jan;166:92-99. doi: 10.1016/j.radonc.2021.10.023. Epub 2021 Nov 5. Radiother Oncol. 2022. PMID: 34748855
Stereotactic radiotherapy needs more evidence before it can be used routinely to treat metastases: A comment on the paper by Nicosia et al.
Macbeth F, Williams N, Treasure T. Macbeth F, et al. Radiother Oncol. 2022 Apr;169:159-160. doi: 10.1016/j.radonc.2022.02.005. Epub 2022 Feb 11. Radiother Oncol. 2022. PMID: 35157977 No abstract available.